The antitumor activities of an estrogen receptor antagonist/degrader (fulvestrant), a RAF/MEK clamp (avutometinib), and a FAK inhibitor (VS-4718) were determined by establishing xenografts from the primary LGSOC tumor sample OVA(K)250. The gene discussed is PTK2; the disease is neoplasm.